Cardiff Oncology, Inc.
NASDAQ:CRDFBiotechnology
+$0.03 today
- Market cap
- $65.27M
- Beta
- 1.38
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.65
Volume 0.86M
Average 1.05M
CRDF Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Cardiff Oncology, Inc.NASDAQ: CRDF
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables turns positive
Q1 FY2026 accounts payables was $0, compared with -$1.05M a year earlier. Trailing-twelve-month accounts payables was $5.21M. Over 3 fiscal years it compounded at +17.8% a year.
Context
- Accounts payables amounted to 371.3% of revenue in FY2025, down 65.7 pp from a year earlier.
- Accounts payables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly accounts payables holds near $0 or moves back toward the trailing-twelve-month quarterly average of $1.3M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 2.2M USD
- Year-over-year change
- -26.2%
- 4-year CAGR
- +32.3%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.2M | -26.2% |
| FY2024 | 2024-12-31 | 2.99M | +5.4% |
| FY2023 | 2023-12-31 | 2.83M | +110.0% |
| FY2022 | 2022-12-31 | 1.35M | +87.5% |
| FY2021 | 2021-12-31 | 719K | — |
Accounts Payables vs competitors
How CRDF compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +1496.2% is the highest of 8, against a peer median of -192.7%.
- Accounts payables amounts to 992.0% of revenue for CRDF, versus a peer median of 20.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $8.06M USD | +141.5% | +199.2% | — | |
| LTM Mar 2026 | $7.58M USD | +55.9% | — | 425.1% | |
| LTM Mar 2026 | $5.21M USD | +1496.2% | +17.8% | 992.0% | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $3.83M USD | -230.5% | — | — |
| LTM Mar 2026 | $3.53M USD | -272.3% | +109.1% | — | |
| LTM Mar 2026 | $2.06M USD | -230.7% | -12.7% | — | |
| LTM Mar 2026 | $662K USD | -192.7% | — | 20.9% | |
| LTM Mar 2026 | CHF 504.13K CHF | -32.5% | — | — | |
| FY2025 | €0 EUR | — | — | 0.0% | |
| Peer median (excluding CRDF) | — | -192.7% | +109.1% | 20.9% | |
Competitors are the stored peer set for CRDF. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (28.29M) | (38.7M) | (41.44M) | (45.43M) | (45.85M) |
| Depreciation & Amortization | 451K | 236K | 398K | 404K | 904K |
| Deferred Income Tax | 1.32M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.23M | 4.26M | 4.51M | 4.76M | 5.69M |
| Change in Working Capital | (1.79M) | (380K) | 6.57M | 3.17M | 2.18M |
| Accounts Receivables | (215K) | (236K) | 483K | (484K) | 591K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 719K | 1.35M | 2.83M | 2.99M | 2.2M |
| Other Working Capital | (2.29M) | (1.49M) | 3.25M | 671K | (614K) |
| Other Non-Cash Items | 2.03M | 772K | (921K) | (598K) | (848K) |
| Operating Cash Flow | (23.04M) | (33.82M) | (30.89M) | (37.69M) | (37.92M) |
| Capital Expenditures | (205K) | (892K) | (582K) | (80K) | (44K) |
| Acquisitions (Net) | 205K | (114K) | 0 | 0 | 0 |
| Purchases of Investments | (174.39M) | (91.23M) | (70.08M) | (23.56M) | (71.12M) |
| Sales of Investments | 43.14M | 130.27M | 106.86M | 37.37M | 73.25M |
| Other Investing Activities | (205K) | 114K | 0 | 0 | (744K) |
| Investing Cash Flow | (131.45M) | 38.15M | 36.2M | 13.73M | 1.34M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 34.19M | 75K | 0 | 53.41M | 2.58M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (24K) | (414K) | 0 | 0 | 0 |
| Other Financing Activities | 1.29M | 414K | 0 | 373K | 0 |
| Financing Cash Flow | 35.45M | 75K | 0 | 53.78M | 2.58M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (119.04M) | 4.4M | 5.31M | 29.82M | (34M) |
| Free Cash Flow | (23.25M) | (34.71M) | (31.47M) | (37.77M) | (37.97M) |
Cardiff Oncology, Inc.
NASDAQ:CRDF
Intrinsic Alpha fair value
Locked
Current Price
$0.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.